Expression of CD10 in Basal Cell Carcinoma

Abstract

We investigated the expression of CD10 by an immunohistochemical method in 51 basal cell carcinomas (BCCs), eight pilomatricomas, five trichoblastomas, two trichofolliculomas, three sebaceomas, five sebaceous carcinomas, ten syringomas, two spiradenomas, ten poromas, four porocarcinomas, one eccrine duct carcinoma (not otherwise specified, NOS), six mixed tumors of apocrine origin, and nine squamous cell carcinomas (SCCs). We detected strong expression of CD10 in tumor cells of BCC (86%), and found that the smaller the number of positive tumor cells, the larger the number of positive stromal cells, in particular in sclerosing BCCs. Spearman's rank correlation test revealed a significant negative correlation in BCCs between the expression of CD10 in tumor cells and that in stromal cells (P = 0.001). In all pilomatricomas (100%) and in four trichoblastomas (80%), strong expression was also detected in tumor cells. There was no detectable expression in trichofolliculomas. One sebaceoma (33%) and two sebaceous carcinomas (40%) expressed CD10 in a similar fashion to BCCs. All tumors of eccrine gland origin, including syringoma, spiradenoma, poroma, porocarcinoma, and eccrine duct carcinoma (NOS), did not express CD10. Five mixed tumors (83%) were immunopositive. In SCC, CD10 was overexpressed only in the stromal cells. These findings support the hypothesis that BCC is derived from the folliculo-sebaceous apocrine unit, especially having the same origin as trichoblastoma and pilomatricoma. CD10 might be an indicator of tumor invasiveness if it is expressed in stromal cells, while it might be a marker of follicular differentiation if it is expressed in the actual tumor cells of cutaneous epithelial neoplasms.

Microcystic adnexal carcinoma: an immunohistochemical reappraisal

“…The strong expression of CD10 in the majority of our cases of infiltrative basal cell carcinoma (60%) is in keeping with previous reports indicating strong expression of CD10 in up to 86-87% of basal cell carcinoma. 32,33 Interestingly enough, while CD10 reportedly only stains the stromal cells in squamous cell carcinoma, we noted CD10 expression in the lesional cells in two cases (25%). 32 A more recent study by Krahl et al 26 indicates absence of BerEP4, a monoclonal antibody recognizing two glycopolypeptides (34 and 39 kDa) found in most human epithelial cells, in all c(13/13) cases of microcystic adnexal carcinoma, and presence in all (28/28) cases of infiltrative basal cell carcinoma, thus attesting to its utility in separating microcystic adnexal carcinoma from infiltrative basal cell carcinoma.…”

“…32,33 Interestingly enough, while CD10 reportedly only stains the stromal cells in squamous cell carcinoma, we noted CD10 expression in the lesional cells in two cases (25%). 32 A more recent study by Krahl et al 26 indicates absence of BerEP4, a monoclonal antibody recognizing two glycopolypeptides (34 and 39 kDa) found in most human epithelial cells, in all c(13/13) cases of microcystic adnexal carcinoma, and presence in all (28/28) cases of infiltrative basal cell carcinoma, thus attesting to its utility in separating microcystic adnexal carcinoma from infiltrative basal cell carcinoma. 34 The utility of this antibody in distinguishing basal cell carcinoma and squamous cell carcinoma based upon its consistent expression in the former and absence in the latter is well documented.…”

Basal cell carcinoma: biology, morphology and clinical implications

“…64 Key to our understanding of the pathogenesis of BCC has been the unraveling of the molecular basis of the nevoid BCC syndrome.…”

CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast

“…With immunohistochemistry (IHC), it can be detected in many hematological malignancies [8,9,10], soft tissue neoplasia (e.g. pleiomorphic undifferentiated sarcoma, fibrosarcomas, leiomyosarcomas and malignant peripheral nerve sheath tumors) [11] as well as in carcinomas of different organs, like the skin [12,13], lung [14], pancreas [15], liver [16], stomach [17], cervix [18], kidney [19], bladder [20] and prostate [21]. Such a wide spectrum of expression may suggest a limitation in the usefulness of CD10 immunostaining in routine diagnostic pathology.…”